Company intelligence / Profile preview

Adrenas Therapeutics, Inc.

Palo Alto, California, United States

Ownership: Private
Development stage: Other

Overview

Adrenas Therapeutics, founded in 2018 and based in California, was a subsidiary of BridgeBio Pharma focused on developing an AAV-based gene therapy for classic congenital adrenal hyperplasia (CAH). Its lead candidate BBP‑631 targeted the CYP21A2 gene using an AAV5 vector. The company initiated a Phase 1/2 trial ("ADventure") in July 2021. In late 2024 or early 2025, BridgeBio discontinued development after enrolling eight patients; no treatment-related serious adverse events were reported. As of early 2025, there are no ongoing clinical programs at Adrenas Therapeutics.

Therapeutic areas: Endocrinology
Modalities: Gene therapy (AAV-based)
Industry: Biotech

Partnerships

National Resilience for manufacturing support during clinical development

Beyond the preview

Go deeper on Adrenas Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adrenas Therapeutics, Inc..

Explore the full profile